# Exelixis, Inc.: overview

EXEL · Nasdaq · CIK 939767 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jan 1

Pages: [Overview](/companies/exel.md) · [Financials](/companies/exel/financials.md) · [Filings](/companies/exel/filings.md) · [Insiders](/companies/exel/insiders.md)

Latest reported revenue: [$658.7m](/filings/0000939767-26-000116.md) for Q3 FY2026, three months to 2026-10-02, from the 10-Q filed Oct 29, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000939767-26-000116).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2025-01-03) | Q1 FY2025 (2025-04-04) | Q2 FY2025 (2025-07-04) | Q3 FY2025 (2025-10-03) | Q4 FY2025 (2026-01-02) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) | Q3 FY2026 (2026-10-02) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [567 d](/filings/0000939767-26-000021.md) | [555](/filings/0000939767-26-000059.md) | [568](/filings/0000939767-26-000098.md) | [598](/filings/0000939767-26-000116.md) | [599 d](/filings/0000939767-26-000021.md) | [611](/filings/0000939767-26-000059.md) | [629](/filings/0000939767-26-000098.md) | [659](/filings/0000939767-26-000116.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [28.8% d](/filings/0000939767-26-000021.md) | [33.6%](/filings/0000939767-26-000059.md) | [37.6%](/filings/0000939767-26-000098.md) | [39.6%](/filings/0000939767-26-000116.md) | [39.3% d](/filings/0000939767-26-000021.md) | [41.1%](/filings/0000939767-26-000059.md) | [39.5%](/filings/0000939767-26-000098.md) | [40.8%](/filings/0000939767-26-000116.md) |
| Net margin | % | [24.7% d](/filings/0000939767-26-000021.md) | [28.7%](/filings/0000939767-26-000059.md) | [32.5%](/filings/0000939767-26-000098.md) | [32.4%](/filings/0000939767-26-000116.md) | [40.8% d](/filings/0000939767-26-000021.md) | [34.5%](/filings/0000939767-26-000059.md) | [33.7%](/filings/0000939767-26-000098.md) | [33.1%](/filings/0000939767-26-000116.md) |
| Diluted EPS | $ per share | not reported | [0.55](/filings/0000939767-26-000059.md) | [0.65](/filings/0000939767-26-000098.md) | [0.69](/filings/0000939767-26-000116.md) | not reported | [0.79](/filings/0000939767-26-000059.md) | [0.82](/filings/0000939767-26-000098.md) | [0.85](/filings/0000939767-26-000116.md) |
| Free cash flow | $m | [236 d](/filings/0000939767-26-000021.md) | [208](/filings/0000939767-26-000059.md) | [46.2 d](/filings/0000939767-26-000098.md) | [289 d](/filings/0000939767-26-000116.md) | [332 d](/filings/0000939767-26-000021.md) | [250](/filings/0000939767-26-000059.md) | [301 d](/filings/0000939767-26-000098.md) | [277 d](/filings/0000939767-26-000116.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-30) | FY2023 (2023-12-29) | FY2024 (2025-01-03) | FY2025 (2026-01-02) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,435](/filings/0000939767-24-000028.md) | [1,611](/filings/0000939767-25-000019.md) | [1,830](/filings/0000939767-26-000021.md) | [2,169](/filings/0000939767-26-000021.md) | [2,320](/filings/0000939767-26-000021.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [20.0%](/filings/0000939767-24-000028.md) | [12.5%](/filings/0000939767-25-000019.md) | [9.3%](/filings/0000939767-26-000021.md) | [27.9%](/filings/0000939767-26-000021.md) | [37.6%](/filings/0000939767-26-000021.md) |
| Net margin | % | [16.1%](/filings/0000939767-24-000028.md) | [11.3%](/filings/0000939767-25-000019.md) | [11.4%](/filings/0000939767-26-000021.md) | [24.0%](/filings/0000939767-26-000021.md) | [33.7%](/filings/0000939767-26-000021.md) |
| Diluted EPS | $ per share | [0.72](/filings/0000939767-24-000028.md) | [0.56](/filings/0000939767-25-000019.md) | [0.65](/filings/0000939767-26-000021.md) | [1.76](/filings/0000939767-26-000021.md) | [2.78](/filings/0000939767-26-000021.md) |
| Free cash flow | $m | [347](/filings/0000939767-24-000028.md) | [335](/filings/0000939767-25-000019.md) | [293](/filings/0000939767-26-000021.md) | [672](/filings/0000939767-26-000021.md) | [876](/filings/0000939767-26-000021.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/exel/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.58bn | 29,075,377 |  | Reduced −1,740,932 |
| [FARALLON CAPITAL MANAGEMENT, L.L.C.](/funds/909661.md) | 2026-06-30 | $732.8m | 13,468,010 |  | Added +357,000 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $730.6m | 13,427,993 |  | Reduced −299,000 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $655.3m | 12,043,122 |  | Reduced −42,151 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $598.6m | 11,023,943 |  | Reduced −2,071,798 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $595.8m | 10,950,997 |  | Reduced −307,987 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $542.5m | 9,970,071 |  | Reduced −328,368 |
| [FULLER & THALER ASSET MANAGEMENT, INC.](/funds/1082327.md) | 2026-06-30 | $485.8m | 8,929,389 |  | Added +387,153 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $416.3m | 7,650,316 |  | Reduced −145,294 |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $302.1m | 5,551,747 |  | Added +1,948,684 |

## Recent filings

[All 1,750 filings](/companies/exel/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 16:16 ET | [10-Q](/filings/0000939767-26-000116.md) | Quarterly report, period 2026-10-02 | 0000939767-26-000116 |
| 2026-10-29 | 16:09 ET | [8-K](/filings/0000939767-26-000114.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000939767-26-000114 |
| 2026-09-11 | 07:00 ET | [8-K](/filings/0000939767-26-000108.md) | 8.01 Other events | 0000939767-26-000108 |
| 2026-08-31 | 16:18 ET | [8-K](/filings/0000939767-26-000104.md) | 8.01 Other events | 0000939767-26-000104 |
| 2026-08-14 | 08:21 ET | [SCHEDULE 13D/A](/filings/0000908834-26-000419.md) | Ownership report, active investor, amended | 0000908834-26-000419 |
| 2026-08-05 | 16:13 ET | [10-Q](/filings/0000939767-26-000098.md) | Quarterly report, period 2026-07-03 | 0000939767-26-000098 |
| 2026-08-05 | 16:09 ET | [8-K](/filings/0000939767-26-000096.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000939767-26-000096 |
| 2026-05-29 | 16:05 ET | [8-K](/filings/0000939767-26-000074.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000939767-26-000074 |
| 2026-05-05 | 16:11 ET | [10-Q](/filings/0000939767-26-000059.md) | Quarterly report, period 2026-04-03 | 0000939767-26-000059 |
| 2026-05-05 | 16:07 ET | [8-K](/filings/0000939767-26-000058.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0000939767-26-000058 |

## Latest annual report

[Form 10-K for the fiscal year ended Jan 2, 2026](/filings/0000939767-26-000021.md), filed Feb 10, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 939767
- Tickers: EXEL
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 17:46 ET. No prices; not investment advice.